KR100975784B1 - 카텝신 시스테인 프로테아제 억제제 - Google Patents
카텝신 시스테인 프로테아제 억제제 Download PDFInfo
- Publication number
- KR100975784B1 KR100975784B1 KR1020047013833A KR20047013833A KR100975784B1 KR 100975784 B1 KR100975784 B1 KR 100975784B1 KR 1020047013833 A KR1020047013833 A KR 1020047013833A KR 20047013833 A KR20047013833 A KR 20047013833A KR 100975784 B1 KR100975784 B1 KR 100975784B1
- Authority
- KR
- South Korea
- Prior art keywords
- leucineamide
- ethyl
- trifluoro
- cyanomethyl
- biphenyl
- Prior art date
Links
- RDLFWUQHKYHEEL-UXMRNZNESA-N CC(C)C[C@@H](C(NCC#N)=O)NC(C(F)(F)F)c1cc(-c(cc2)ccc2N2CCNCC2)ccc1 Chemical compound CC(C)C[C@@H](C(NCC#N)=O)NC(C(F)(F)F)c1cc(-c(cc2)ccc2N2CCNCC2)ccc1 RDLFWUQHKYHEEL-UXMRNZNESA-N 0.000 description 1
- BPNYGROKNLQWGN-SVBPBHIXSA-N CC(C)C[C@@H](C(NCC#N)=O)N[C@@H](c(cc1)ccc1-c(cc1)ccc1S(C)(=O)=O)c(ccc(F)c1)c1F Chemical compound CC(C)C[C@@H](C(NCC#N)=O)N[C@@H](c(cc1)ccc1-c(cc1)ccc1S(C)(=O)=O)c(ccc(F)c1)c1F BPNYGROKNLQWGN-SVBPBHIXSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/17—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and doubly-bound oxygen atoms bound to the same acyclic carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
- C07C255/25—Aminoacetonitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
- C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
- Epoxy Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
Description
N2-[(S)-(4-브로모페닐)(4-브로모티엔-2-일)메틸]-N1-(시아노메틸)-L-류신아미드;
실시예 15
실시예 19
실시예 32
실시예 33
카텝신 K 분석
Claims (28)
- 하기 화학식 I의 화합물, 또는 이의 약제학적으로 허용되는 염, 입체이성체 또는 N-옥사이드 유도체.화학식 I상기 화학식 I에서,R1은 수소, C1-6 알킬 또는 C2-6 알케닐이고, 여기서 상기 알킬 및 알케닐 그룹은 치환되지 않거나 1 내지 6개의 할로, C3-6 사이클로알킬, -SR9, -SR12, -SOR9, -SOR12, -SO2R9, -SO2R12, -SO2CH(R12)(R11), -OR12, -OR9, -N(R12)2, 아릴, 헤테로아릴 또는 헤테로사이클릴로 치환되며, 이때 상기 아릴, 헤테로아릴 및 헤테로사이클릴 그룹은 치환되지 않거나 독립적으로 C1-6 알킬, 할로, 하이드록시알킬, 하이드록시, 알콕시 또는 케토로부터 선택된 1 또는 2개의 치환체로 치환되고;R2는 수소, C1-6 알킬 또는 C2-6 알케닐이고, 여기서 상기 알킬 및 알케닐 그룹은 치환되지 않거나 1 내지 6개의 할로, C3-6 사이클로알킬, -SR9, -SR12, -SOR9, -SOR12, -SO2R9, -SO2R12, -SO2CH(R12)(R11), -OR12, -OR9, -N(R12)2, 아릴, 헤테로아릴 또는 헤테로사이클릴로 치환되며, 이때 상기 아릴, 헤테로아릴 및 헤테로사이클릴 그룹은 치환되지 않거나 독립적으로 C1-6 알킬, 할로, 하이드록시알킬, 하이드록시, 알콕시 또는 케토로부터 선택되는 1 또는 2개의 치환체로 치환되거나;R1 및 R2는, 이들이 결합된 탄소 원자와 함께, C3-8 사이클로알킬 또는 헤테로사이클릴 환을 형성할 수 있고, 여기서 상기 환 시스템은 치환되지 않거나 독립적으로 C1-6 알킬, 하이드록시알킬, 할로알킬 또는 할로로부터 선택된 1 또는 2개의 치환체로 치환되고;R3은 수소, C1-6 알킬 또는 C2-6 알케닐이고, 여기서 상기 알킬 및 알케닐 그룹은 치환되지 않거나 C3-6 사이클로알킬 또는 1 내지 6개의 할로로 치환되며;R4는 수소, C1-6 알킬 또는 C2-6 알케닐이고, 여기서 상기 알킬 및 알케닐 그룹은 치환되지 않거나 C3-6 사이클로알킬 또는 1 내지 6개의 할로로 치환되거나;R3 및 R4는, 이들이 결합된 탄소 원자와 함께, C3-8 사이클로알킬 환, C5-8 사이클로알케닐 환, 또는 5 내지 7원의 헤테로사이클릴을 형성할 수 있고, 여기서 상기 사이클로알킬, 사이클로알케닐 및 헤테로사이클릴 그룹은 치환되지 않거나 독립적으로 C1-6 알킬, 할로, 하이드록시알킬, 하이드록시, 알콕시 또는 케토로부터 선택된 1 또는 2개의 치환체로 치환되며;R5는 수소 또는 1 내지 6개의 할로로 치환된 C1-6 알킬로부터 선택되고;R6은 아릴, 헤테로아릴, C1-6 할로알킬, 아릴알킬 또는 헤테로아릴알킬이고, 여기서 상기 아릴, 헤테로아릴, 아릴알킬 및 헤테로아릴알킬 그룹은 치환되지 않거나 독립적으로 할로, C1-6 알킬, C1-6 할로알킬, C3-6 사이클로알킬, 할로알콕시, -SR9, -SR12, -SOR9, -SOR12, -SO2R9, -SO2R12, -SO2CH(R12)(R11), -OR12, -N(R10)(R11), 시아노, 또는 치환되지 않거나 -SO2R12로 치환된 아릴로부터 선택된 1 내지 3개의 치환체로 치환되며;각각의 D는 독립적으로 C1-3 알킬, C2-3 알케닐, C2-3 알키닐, 아릴, 헤테로아릴, C3-8 사이클로알킬 또는 헤테로사이클릴이고, 여기서 각각의 상기 아릴, 헤테로아릴, 사이클로알킬 및 헤테로사이클릴 그룹은 모노사이클릭 또는 바이사이클릭일 수 있고 치환되지 않거나 탄소 또는 헤테로원자상에서 독립적으로 C1-6 알킬, 할로알킬, 할로, 케토, 알콕시, -SR9, -SR12, -OR9, -OR12, N(R12)2, -SO2R9 또는 -SO2R10으로부터 선택된 1 내지 5개의 치환체로 치환되며;R7은 수소, C1-6 알킬, C2-6 알케닐, C2-6 알키닐, C1-6 알킬옥시, 할로, 니트로, 시아노, 아릴, 헤테로아릴, C3-8 사이클로알킬, 헤테로사이클릴, -C(O)OR10, -C(O)OSi[CH(CH3)2]3, -OR9, -OR10, -C(O)R10, -R10C(O)R9, -C(O)R9, -C(O)N(Ra)(Rb), -C(O)N(R12)(R12), -C(O)N(R10)(R11), -C(R10)(R11)OH, -SR12, -SR9, -R10SR9, -R9, -C(R9)3, -C(R10)(R11)N(R9)2, -NR10C(O)NR10S(O)2R9, -SO2R12, -SO(R12), -SO2R9, -SOmN(Rc)(Rd), -SOmCH(R10)(R11), -SO2N(R10)C(O)(R12), -SO2(R10)C(O)N(R12)2, -OSO2R10, -N(R10)(R11), -N(R10)C(O)N(R10)(R9), -N(R10)C(O)R9, -N(R10)C(O)R10, -N(R10)C(O)OR10, -N(R10)SO2(R10), -C(R10)(R11)NR10C(R10)(R11)R9, -C(R10)(R11)N(R10)R9, -C(R10)(R11)N(R10)(R11), -C(R10)(R11)SC(R10)(R11)(R9), R10S-, -C(Ra)(Rb)NRaC(Ra)(Rb)(R9), -C(Ra)(Rb)N(Ra)(Rb), -C(Ra)(Rb)C(Ra)(Rb)N(Ra)(Rb), -C(O)C(Ra)(Rb)N(Ra)(Rb), -C(Ra)(Rb)N(Ra)C(O)R9, -C(O)C(Ra)(Rb)S(Ra), C(Ra)(Rb)C(O)N(Ra)(Rb), -B(OH)2, -OCH2O- 또는 4,4,5,5-테트라메틸-1,3,2-디옥사보롤란-2-일이고; 여기서, 상기 그룹은 치환되지 않거나 탄소 또는 헤테로원자상에서 독립적으로 C1-6 알킬, 할로, 케토, 시아노, 할로알킬, 하이드록시알킬, -OR9, -NO2, -NH2, -NHS(O)2R8, -R9SO2R12, -SO2R12, -SO(R12), -SR12, -SR9, -SOmN(Rc)(Rd), -SOmN(R10)C(O)(R12), -C(R10)(R11)N(R10)(R11), -C(R10)(R11)OH, -COOH, -C(Ra)(Rb)C(O)N(Ra)(Rb), -C(O)(Ra)(Rb), -N(R10)C(R10)(R11)(R9), -N(R10)CO(R9), -NH(CH2)2OH, -NHC(O)OR10, -Si(CH3)3, 헤테로사이클릴, 아릴 또는 헤테로아릴로부터 선택된 1 내지 5개의 치환체로 치환되며;R8은 수소 또는 C1-6 알킬이거나;R4 및 R8은, 이들이 결합된 임의의 원자와 함께, 또는 이들 사이에서, 4 내지 10원의 헤테로사이클릴 환 시스템을 형성할 수 있고, 여기서 상기 환 시스템은 모노사이클릭 또는 바이사이클릭일 수 있고, 치환되지 않거나 독립적으로 C1-6 알킬, 할로, 하이드록시알킬, 하이드록시, 케토, -OR10, -SR10 또는 -N(R10)2로부터 선택된 1 또는 2개의 치환체로 치환되며;R9는 수소, 아릴, 아릴(C1-4)알킬, 헤테로아릴, 헤테로아릴(C1-4)알킬, C3-8사이클로알킬, C3-8사이클로알킬(C1-4)알킬 및 헤테로사이클릴(C1-4)알킬로 이루어진 그룹으로부터 선택되고, 여기서 상기 그룹은 치환되지 않거나 독립적으로 할로, 알콕시 또는 -SO2R12로부터 선택된 1 내지 3개의 치환체로 치환될 수 있으며;R10은 수소 또는 C1-6 알킬이고;R11은 수소 또는 C1-6 알킬이며;R12는 수소 또는 치환되지 않거나 독립적으로 할로, 알콕시, 시아노, -NR10 또는 -SR10으로부터 선택된 1 내지 3개의 치환체로 치환된 C1-6 알킬이고;Ra는 수소, C1-6 알킬, (C1-6 알킬)아릴, (C1-6 알킬)하이드록실, -O(C1-6 알킬), 하이드록실, 할로, 아릴, 헤테로아릴, C3-8 사이클로알킬 또는 헤테로사이클릴이고, 여기서 상기 알킬, 아릴, 헤테로아릴, C3-8 사이클로알킬 및 헤테로사이클릴은 치환되지 않거나 탄소 또는 헤테로원자상에서 독립적으로 C1-6 알킬 또는 할로로부터 선택된 1 내지 3개의 치환체로 치환될 수 있으며;Rb는 수소, C1-6 알킬, (C1-6 알킬)아릴, (C1-6 알킬)하이드록실, 알콕실, 하이드록실, 할로, 아릴, 헤테로아릴, C3-8 사이클로알킬 또는 헤테로사이클릴이고, 여기서 상기 알킬, 아릴, 헤테로아릴, C3-8 사이클로알킬 및 헤테로사이클릴은 치환되지 않거나 탄소 또는 헤테로원자상에서 독립적으로 C1-6 알킬 또는 할로로부터 선택된 1 내지 3개의 치환체로 치환될 수 있거나;Ra 및 Rb는, 이들이 결합된 탄소 원자와 함께, 또는 이들 사이에서, C3-8 사이클로알킬 환 또는 C3-8 헤테로사이클릴 환을 형성할 수 있고, 여기서 상기 3 내지 8원의 환 시스템은 치환되지 않거나 독립적으로 C1-6 알킬 및 할로로부터 선택된 1 또는 2개의 치환체로 치환될 수 있으며;Rc는 수소 또는 치환되지 않거나 독립적으로 할로 또는 -OR9로부터 선택된 1 내지 3개의 치환체로 치환된 C1-6 알킬이고;Rd는 수소 또는 치환되지 않거나 독립적으로 할로 또는 -OR9로부터 선택된 1 내지 3개의 치환체로 치환된 C1-6 알킬이거나;Rc 및 Rd는, 이들이 결합된 질소 원자와 함께, 또는 이들 사이에서, 치환되지 않거나 독립적으로 C1-6 알킬, 할로 하이드록시알킬, 하이드록시, 알콕시 또는 케토로부터 선택된 1 또는 2개의 치환체로 치환된 C3-8 헤테로사이클릴 환을 형성할 수 있고;n은 독립적으로 정수 1 내지 3으로부터 선택되며;각각의 m은 독립적으로 정수 0 내지 2로부터 선택된다.
- 제1항에 있어서, R1이 수소이고 R2가 수소이거나, R1 및 R2가, 이들이 결합된 탄소원자와 함께, C3-8 사이클로알킬 환을 형성하고, 이때 상기 환 시스템은 치환되지 않거나 C1-6 알킬 또는 할로로부터 선택된 1 또는 2개의 치환체로 치환된, 화학식 I의 화합물, 또는 이의 약제학적으로 허용되는 염, 입체이성체 또는 N-옥사이드 유도체.
- 제2항에 있어서, R3이 치환되지 않거나 1 내지 6개의 할로로 치환된 C1-6 알킬이고, R4가 수소인, 화학식 I의 화합물, 또는 이의 약제학적으로 허용되는 염, 입체이성체 또는 N-옥사이드 유도체.
- 제3항에 있어서, R3이 n-프로필, 이소부틸, 2-플루오로-2-메틸프로필, 2-트리플루오로메틸프로필, 3-플루오로-2-(2-플루오로메틸)프로필, 2,2-디플루오로에틸, 2,2-디플루오로프로필, 3,3,3-트리플루오로프로필, 또는 2,2-디클로로에틸이고, R4가 수소인, 화학식 I의 화합물, 또는 이의 약제학적으로 허용되는 염, 입체이성체 또는 N-옥사이드 유도체.
- 제3항에 있어서, R5가 수소이고 R6이 치환되지 않거나 할로 또는 -SO2R12로부터 선택된 1 내지 3개의 치환체로 치환된 아릴 또는 헤테로아릴인, 화학식 I의 화합물, 또는 이의 약제학적으로 허용되는 염, 입체이성체 또는 N-옥사이드 유도체.
- 제3항에 있어서, R5가 수소이고 R6이 1 내지 6개의 할로로 치환된 C1-6 알킬인, 화학식 I의 화합물, 또는 이의 약제학적으로 허용되는 염, 입체이성체 또는 N-옥사이드 유도체.
- 제6항에 있어서, R5가 수소이고 R6이 트리플루오로메틸 또는 3,3,3,2,2-펜타플루오로에틸인, 화학식 I의 화합물, 또는 이의 약제학적으로 허용되는 염, 입체이성체 또는 N-옥사이드 유도체.
- 제6항에 있어서, n이 2이고, 각각의 D가 독립적으로 아릴 또는 헤테로아릴이며, R7이 -SOmCH(R10)(R11) 또는 -SOm(Rc)(Rd)이고, Rc 및 Rd가 각각 독립적으로 수소 또는 C1-6 알킬인, 화학식 I의 화합물, 또는 이의 약제학적으로 허용되는 염, 입체이성체 또는 N-옥사이드 유도체.
- 제1항에 있어서,N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(시아노메틸)-N2-(2,2,2-트리플루오로-1-페닐에틸)-L-류신아미드;N1-(시아노메틸)-N2-[2,2,2-트리플루오로-1-(4-플루오로-3-메틸페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1R)-2,2,2-트리플루오로-1-(4-피리딘-3-일페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4-피리딘-3-일페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1R)-2,2,2-트리플루오로-1-(4-피리딘-4-일페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4-피리딘-4-일페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1R)-2,2,2-트리플루오로-1-(4-{[4-(2-플루오로에틸)피페라진-1-일]카보닐}페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[2,2,2-트리플루오로-1-(4-{[4-(2-플루오로에틸)피페라진-1-일]카보닐}페닐)에틸]-L-류신아미드;N2-[1-(1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{2,2,2-트리플루오로-1-[4-(3-하이드록시-3-메틸부트-1-인일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(3-하이드록시-3-메틸부틸)페닐]에틸}-L-류신아미드;N2-[(1S)-1-(4-브로모페닐)-2,2,3,3,3-펜타플루오로프로필]-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,3,3,3-펜타플루오로-1-(4-피리딘-4-일페닐)프로필]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4'-플루오로-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N1-(시아노메틸)-N2-((1S)-2,2,2-트리플루오로-1-{4-[(1E)-3-하이드록시-3-메틸부트-1-에닐]페닐}에틸)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,3,3,3-펜타플루오로-1-[4'-(메틸티오)-1,1'-바이페닐-4-일]프로필}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,3,3,3-펜타플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]프로필}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(1-옥시도피리딘-3-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(모르폴린-4-일카보닐)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4-{[메톡시(메틸)아미노]카보닐}페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4-티엔-3-일페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(4-메틸피리딘-2-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(5-메틸피리딘-2-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(2'-플루오로-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-1-[4-(3,5-디메틸이속사졸-4-일)페닐]-2,2,2-트리플루오로에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(하이드록시메틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N2-[(1S)-1-(4'-시아노-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-1-(3',4'-디플루오로-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-L-류신아미드;4'-{1-[1-(시아노메틸-카바모일)-3-메틸-부틸아미노]-2,2,2-트리플루오로-에틸}-바이페닐-2-카복실산 메틸 에스테르;4'-{1-[1-(시아노메틸-카바모일)-3-메틸-부틸아미노]-2,2,2-트리플루오로-에틸}-바이페닐-3-카복실산 메틸 에스테르;N1-(시아노메틸)-N2-[(1S)-1-(3',4'-디메톡시-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[2'-(트리플루오로메틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-1-(3',4'-디클로로-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(3'-포르밀-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(2-옥소-2,3-디하이드로-1,3-벤조티아졸-6-일)페닐]에틸}-L-류신아미드;N2-{(1S)-1-[4-(5-브로모피리딘-3-일)페닐]-2,2,2-트리플루오로에틸}-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(트리플루오로메톡시)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(1H-인돌-4-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4-피리미딘-5-일페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4-퀴놀린-3-일페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(1,3-티아졸-2-일)페닐]에틸}-L-류신아미드;4'-{1-[1-(시아노메틸-카바모일)-3-메틸-부틸아미노]-2,2,2-트리플루오로-에틸}-바이페닐-4-카복실산 메틸 에스테르;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4-피리미딘-2-일페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(3-메틸피리딘-2-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(3-푸릴)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-((1S)-2,2,2-트리플루오로-1-{4-[3-(트리플루오로메틸)피리딘-2-일]페닐}에틸)-L-류신아미드;N1-(시아노메틸)-N2-((1S)-2,2,2-트리플루오로-1-{4-[4-(트리플루오로메틸)피리딘-2-일]페닐}에틸)-L-류신아미드;N1-(시아노메틸)-N2-((1S)-2,2,2-트리플루오로-1-{4-[5-(트리플루오로메틸)피리딘-2-일]페닐}에틸)-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(3'-메톡시-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(3'-메톡시-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N2-{(1S)-1-[4'-(아세틸아미노)-3'-플루오로-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(3-메틸티엔-2-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(3'-플루오로-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N2-{(1S)-1-[4-(5-아세틸티엔-2-일)페닐]-2,2,2-트리플루오로에틸}-N1-(시아노메틸)-L-류신아미드;N2-[(1S)-1-(3'-아세틸-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[3'-(트리플루오로메틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(5'-플루오로-2'-메톡시-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-1-(3',5'-디플루오로-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(2',3',5'-트리플루오로-1,1'-바이페닐-4-일)에틸]-L-류신아미드;3-(4'-{1-[1-(시아노메틸-카바모일)-3-메틸-부틸아미노]-2,2,2-트리플루오로-에틸}-바이페닐-3-일)-아크릴산;N2-{(1S)-1-[4-(9-안트릴)페닐]-2,2,2-트리플루오로에틸}-N1-(시아노메틸)-L-류신아미드;N2-[(1S)-1-(4'-벤조일-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-L-류신아미드;N2-[(1S)-1-(3'-아세틸-4'-하이드록시-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-1-[2'-(시아노메틸)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-L-류신아미드;N1-(시아노메틸)-N2-{2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{2,2,2-트리플루오로-1-[4'-(메틸설피닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(시아노메틸)-N2-[2,2,2-트리플루오로-1-(4-모르폴린-4-일페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-{(1R)-2,2,2-트리플루오로-1-[4-(6-메틸피리딘-3-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(6-메틸피리딘-3-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-[2,2,2-트리플루오로-1-(5-페닐티엔-2-일)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[2,2,2-트리플루오로-1-(4-퀴놀린-8-일페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4-피리딘-2-일페닐)에틸]-L-류신아미드;N2-{1-[4'-(아미노설포닐)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-N1-(시아노메틸)-L-류신아미드;N2-{(1S)-1-[4'-(아미노설포닐)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸티오)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N2-[(1S)-1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{(1R)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(모르폴린-4-일설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(이소프로필설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N2-{(1S)-1-[4'-(아미노설포닐)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-N1-(시아노메틸)-L-류신아미드;N2-((1S)-1-{4'-[(아세틸아미노)설포닐]-1,1'-바이페닐-4-일}-2,2,2-트리플루오로에틸)-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[2'-메틸-4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N2-[1-(5-브로모티엔-2-일)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-L-류신아미드;N2-[1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-L-류신아미드;4-(4'-{1-[1-(시아노메틸-카바모일)-3-메틸-부틸아미노]-2,2,2-트리플루오로-에틸}-바이페닐-4-일)-피페라진-1-카복실산 3급-부틸 에스테르;N1-(시아노메틸)-N2-[2,2,2-트리플루오로-1-(4'-피페라진-1-일-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N1-(시아노메틸)-N2-(2,2,2-트리플루오로-1-{4'-[4-(2-하이드록시에틸)피페라진-1-일]-1,1'-바이페닐-4-일}에틸)-L-류신아미드;N1-(시아노메틸)-N2-(2,2,2-트리플루오로-1-{4'-[4-(2-하이드록시-2-메틸프로필)피페라진-1-일]-1,1'-바이페닐-4-일}에틸)-L-류신아미드;N1-(시아노메틸)-N2-(1-{4-[(디메틸아미노)카보닐]페닐}-2,2,2-트리플루오로에틸)-L-류신아미드;N1-(시아노메틸)-N2-[2,2,2-트리플루오로-1-(4'-피페라진-1-일-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N1-(시아노메틸)-N2-(1-{4-[(사이클로프로필아미노)카보닐]페닐}-2,2,2-트리플루오로에틸)-L-류신아미드;4-{1-[1-(시아노메틸-카바모일)-3-메틸-부틸아미노]-2,2,2-트리플루오로-에틸}-벤조산;N1-(시아노메틸)-N2-(2,2,2-트리플루오로-1-{4'-[4-(2-플루오로에틸)피페라진-1-일]-1,1'-바이페닐-4-일}에틸)-L-류신아미드;N1-(시아노메틸)-N2-(2,2,2-트리플루오로-1-{4-[(4-메틸피페라진-1-일)카보닐]페닐}에틸)-L-류신아미드;N1-(시아노메틸)-N2-[2,2,2-트리플루오로-1-(4-{[4-(2-하이드록시-2-메틸프로필)피페라진-1-일]카보닐}페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(2-메틸-1,3-티아졸-4-일)페닐]에틸}-L-류신아미드;N2-{1-[4-(3-3급-부틸-1,2,4-트리아진-5-일)페닐]-2,2,2-트리플루오로에틸}-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-[2,2,2-트리플루오로-1-(4-{2-[3-(메틸설포닐)페닐]-1,3-티아졸-4-일}페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-((1S)-2,2,2-트리플루오로-1-{4-[2-(1H-피라졸-4-일)-1,3-티아졸-4-일]페닐}에틸)-L-류신아미드;N1-(시아노메틸)-N2-(2,2,2-트리플루오로-1-{4'-[4-(메틸설포닐)피페라진-1-일]-1,1'-바이페닐-4-일}에틸)-L-류신아미드;N2-[1-(3-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{2,2,2-트리플루오로-1-[4'-(메틸티오)-1,1'-바이페닐-3-일]에틸}-L-류신아미드;N1-(시아노메틸)-N2-[2,2,2-트리플루오로-1-(3-피리딘-4-일페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[2,2,2-트리플루오로-1-(4'-피페라진-1-일-1,1'-바이페닐-3-일)에틸]-L-류신아미드;N1-(시아노메틸)-N2-{2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-3-일]에틸}-L-류신아미드;N-(시아노메틸)-1-[(2,2,2-트리플루오로-1-페닐에틸)아미노]사이클로헥산카복사미드;1-{[1-(4-브로모페닐)-2,2,2-트리플루오로에틸]아미노}-N-(시아노메틸)사이클로헥산카복사미드;N-(시아노메틸)-1-{[2,2,2-트리플루오로-1-(4'-피페라진-1-일-1,1'-바이페닐-4-일)에틸]아미노}사이클로헥산카복사미드;N1-(시아노메틸)-N2-[2,2,2-트리플루오로-1-(4-피페리딘-4-일페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-{2,2,2-트리플루오로-1-[4-(4-피리딘-2-일피페라진-1-일)페닐]에틸}-L-류신아미드;N2-[1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-3-사이클로프로필알라닌아미드;N1-(시아노메틸)-3-사이클로프로필-N2-[2,2,2-트리플루오로-1-(4-피리딘-4-일페닐)에틸]알라닌아미드;N1-(시아노메틸)-N2-[2,2,2-트리플루오로-1-(4'-피리딘-4-일-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1R)-2,2,2-트리플루오로-1-(1,3-티아졸-2-일)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4'-메톡시-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4-메톡시페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4'-피리딘-4-일-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4-페녹시페닐)에틸]-L-류신아미드;N2-[(1S)-1-(4'-브로모-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-L-류신아미드;N2-{(1S)-1-[4-(4-클로로피리딘-3-일)페닐]-2,2,2-트리플루오로에틸}-N1-(시아노메틸)-L-류신아미드;N2-{(1S)-1-[4'-(아세틸아미노)-2'-메틸-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-N1-(시아노메틸)-L-류신아미드;N2-[(1S)-1-(1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(6-메톡시피리딘-3-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(6-메톡시피리딘-2-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4''-(메틸설포닐)-1,1':4',1''-터페닐-4-일]에틸}-L-류신아미드;N2-[(1S)-1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-3-(1-메틸사이클로프로필)-L-알라닌아미드;N1-(시아노메틸)-3-(1-메틸사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-알라닌아미드;N1-(시아노메틸)-3-(1-메틸사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸티오)-1,1'-바이페닐-4-일]에틸}-L-알라닌아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4'-메틸-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N2-[(1S)-1-(4'-아세틸-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(하이드록시메틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N2-[1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-D-류신아미드;N1-(시아노메틸)-N2-{2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-D-류신아미드;N1-(시아노메틸)-N2-{2,2,2-트리플루오로-1-[4'-(모르폴린-4-일설포닐)-1,1'-바이페닐-4-일]에틸}-D-류신아미드;N1-(시아노메틸)-N2-(2,2,2-트리플루오로-1-{4'-[(메틸아미노)설포닐]-1,1'-바이페닐-4-일}에틸)-D-류신아미드;N1-(시아노메틸)-N2-{(1R)-2,2,2-트리플루오로-1-[4-(1-옥시도피리딘-4-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{2,2,2-트리플루오로-1-[4-(1-옥시도피리딘-4-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-(2,2,2-트리플루오로-1-{4-[6-(1-하이드록시-1-메틸에틸)-1-옥시도피리딘-3-일]페닐}에틸)-L-류신아미드;N1-(시아노메틸)-N2-(2,2,2-트리플루오로-1-{4-[6-(메틸설포닐)피리딘-3-일]페닐}에틸)-L-류신아미드;N1-(시아노메틸)-N2-(2,2,2-트리플루오로-1-{4-[2-(4-메틸피페라진-1-일)-1,3-티아졸-4-일]페닐}에틸)-L-류신아미드;N2-[1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-L-류신아미드;N1-(시아노메틸)-N2-[2,2,2-트리플루오로-1-(4-피페라진-1-일페닐)에틸]-L-류신아미드;N2-{1-[3'-(아세틸아미노)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{2,2,2-트리플루오로-1-[4-(4-프로필피페라진-1-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{2,2,2-트리플루오로-1-[4-(피페라진-1-일카보닐)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-[2,2,2-트리플루오로-1-(4-{[4-(2-하이드록시에틸)피페라진-1-일]카보닐}페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4-{3-[3-(트리플루오로메틸)페닐]-1,2,4-옥사디아졸-5-일}페닐)에틸]-L-류신아미드;4-{1-[1-(시아노메틸-카바모일)-3-메틸-부틸아미노]-2,2,2-트리플루오로-에틸}-벤조산 메틸 에스테르;N1-(시아노메틸)-N2-((1S)-2,2,2-트리플루오로-1-{4-[(E)-2-퀴놀린-2-일에테닐]페닐}에틸)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(3-메틸-1,2,4-옥사디아졸-5-일)페닐]에틸}-L-류신아미드;N2-((1S)-1-{4-[3-(5-브로모피리딘-3-일)-1,2,4-옥사디아졸-5-일]페닐}-2,2,2-트리플루오로에틸)-N1-(시아노메틸)-L-류신아미드;N2-[(1S)-1-(4-벤조일페닐)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(티엔-2-일카보닐)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(1,3-티아졸-2-일카보닐)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4-{(Z)-2-[4-(메틸설포닐)페닐]에테닐}페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4-{(E)-2-[4-(메틸설포닐)페닐]에테닐}페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4-이소부티릴페닐)에틸]-L-류신아미드;N2-{(1S)-1-[4-(4-브로모-1,3-티아졸-2-일)페닐]-2,2,2-트리플루오로에틸}-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-1-(4-시아노페닐)-2,2,2-트리플루오로에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-1-(4-에티닐페닐)-2,2,2-트리플루오로에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(2'-플루오로-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(1,3-티아졸-2-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{2,2,2-트리플루오로-1-[4'-(메틸티오)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{2,2,2-트리플루오로-1-[4-(2-메틸퀴놀린-7-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{2,2,2-트리플루오로-1-[4-(1H-인돌-5-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{1-[4'-(디메틸아미노)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-1-(4-{[(시아노메틸)아미노]카보닐}페닐)-2,2,2-트리플루오로에틸]-L-류신아미드;N1-(시아노메틸)-N2-[(1R)-1-(4-{[(시아노메틸)아미노]카보닐}페닐)-2,2,2-트리플루오로에틸]-L-류신아미드;N1-(시아노메틸)-N2-{2,2,2-트리플루오로-1-[3'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;4'-{1-[1-(시아노메틸-카바모일)-3-메틸-부틸아미노]-2,2,2-트리플루오로-에틸}-바이페닐-4-카복실산;4'-{1-[1-(시아노메틸-카바모일)-3-메틸-부틸아미노]-2,2,2-트리플루오로-에틸}-바이페닐-4-카복실산 메톡시-메틸-아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-({[4-(메틸설포닐)벤질]티오}메틸)페닐]에틸}-L-류신아미드;N2-{(1S)-1-[4-(5-클로로피리딘-2-일)페닐]-2,2,2-트리플루오로에틸}-N1-(시아노메틸)-L-류신아미드;N2-{(1S)-1-[3'-(아미노설포닐)-4'-브로모-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-N1-(시아노메틸)-L-류신아미드;N2-{(1S)-1-[4'-브로모-3'-(메틸설포닐)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-((1S)-2,2,2-트리플루오로-1-{4-[5-메틸-6-(메틸설포닐)피리딘-3-일]페닐}에틸)-L-류신아미드;N2-[(1S)-1-(4-{5-클로로-3-[4-(메틸설포닐)페닐]피리딘-2-일}페닐)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-L-류신아미드N1-(시아노메틸)-N2-((1S)-2,2,2-트리플루오로-1-{4-[(페닐티오)메틸]페닐}에틸)-L-류신아미드;N1-(시아노메틸)-N2-((1S)-2,2,2-트리플루오로-1-{4'-[(트리플루오로메틸)설포닐]-1,1'-바이페닐-4-일}에틸)-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4-{[(4-플루오로벤조일)아미노]메틸}페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(메틸설포닐)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-1-[4'-(에틸설포닐)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-L-류신아미드;N2-((1S)-1-{4-[({[3-(2-클로로-6-플루오로페닐)-5-메틸이속사졸-4-일]카보닐}아미노)메틸]페닐}-2,2,2-트리플루오로에틸)-N1-(시아노메틸)-L-류신아미드;N2-((1S)-1-{4-[(9-클로로-3-메틸-4-옥소이속사졸로[4,3-c]퀴놀린-5(4H)-일)메틸]페닐}-2,2,2-트리플루오로에틸)-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-메톡시-3'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N2-{(1S)-1-[4''-클로로-4'-(메틸설포닐)-1,1':2',1''-터페닐-4-일]-2,2,2-트리플루오로에틸}-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[2'-메톡시-4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N2-{(1S)-1-[2'-클로로-4'-(메틸설포닐)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-((1S)-2,2,2-트리플루오로-1-{4'-[(2-하이드록시에틸)티오]-1,1'-바이페닐-4-일}에틸)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[3'-플루오로-4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(시아노메틸)-N2-((1S)-2,2,2-트리플루오로-1-{4'-[(2-하이드록시에틸)설포닐]-1,1'-바이페닐-4-일}에틸)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[3'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-({2-[메톡시(메틸)아미노]-2-옥소에틸}설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(시아노메틸)-N2-((1S)-2,2,2-트리플루오로-1-{4'-[(2-하이드록시-2-메틸프로필)설포닐]-1,1'-바이페닐-4-일}에틸)-L-류신아미드;N2-{(1S)-1-[4'-(아미노설포닐)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-N1-(1-시아노사이클로프로필)-L-류신아미드;N2-[(4-브로모페닐)(2,4,6-트리플루오로페닐)메틸]-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-[(4-피리딘-4-일페닐)(2,4,6-트리플루오로페닐)메틸]-L-류신아미드;N1-(시아노메틸)-N2-[[4-(4-플루오로벤질)페닐](페닐)메틸]-L-류신아미드;N1-(시아노메틸)-N2-{페닐[4-(피리딘-3-일메틸)페닐]메틸}-L-류신아미드;N2-{(4-브로모페닐)[4-(메틸설포닐)페닐]메틸}-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{[4-(메틸설포닐)페닐][4'-(메틸티오)-1,1'-바이페닐-4-일]메틸}-L-류신아미드;N1-(시아노메틸)-N2-{[4'-(메틸설포닐)-1,1'-바이페닐-4-일][4-(메틸설포닐)페닐]메틸}-L-류신아미드;N1-(시아노메틸)-N2-[2,2,2-트리클로로-1-(4-글리콜로일페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-[2-플루오로-1-(플루오로메틸)-1-페닐에틸]-L-류신아미드;N1-(시아노메틸)-N2-{2,2,2-트리플루오로-1-[4-(피롤리딘-1-일아세틸)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{2,2,2-트리플루오로-1-[4-(피페라진-1-일카보닐)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-(2,2,2-트리플루오로-1-{4-[2-(4-메틸피페라진-1-일)-1,3-티아졸-4-일]페닐}에틸)-L-류신아미드;N1-(1-시아노사이클로프로필)-3-(1-메틸사이클로프로필)-N2-(2,2,2-트리플루오로-1-{4-[1-(2-하이드록시에틸)프롤릴]페닐}에틸)-L-알라닌아미드;N2-[[4-(4-3급-부틸피페라진-1-일)페닐](펜타플루오로페닐)메틸]-N1-(시아노메틸)-L-류신아미드;N-(시아노메틸)-1-{1-[4-(4-메틸피페라진-1-일)페닐]에틸}피페리딘-2-카복사미드;N2-[[4-(4-3급-부틸피페라진-1-일)페닐](피리딘-2-일)메틸]-N1-(시아노메틸)-L-류신아미드;N2-{[4-(4-3급-부틸피페라진-1-일)페닐][5-(트리플루오로메틸)피리딘-2-일]메틸}-N1-(시아노메틸)-L-류신아미드;(4S)-N-(시아노메틸)-4-메틸-1-[(1S)-1-(4-피페라진-1-일페닐)에틸]-L-프롤린아미드;(4S)-N-(시아노메틸)-4-메틸-1-[(1R)-1-(4-피페라진-1-일페닐)에틸]-L-프롤린아미드;N-(시아노메틸)-1-[(1S)-1-(4-피페라진-1-일페닐)에틸]-L-프롤린아미드;N-(시아노메틸)-1-[(1R)-1-(4-피페라진-1-일페닐)에틸]-L-프롤린아미드;N-(시아노메틸)-4,4-디플루오로-1-[(1S)-1-(4-피페라진-1-일페닐)에틸]-L-프롤린아미드;N1-(1-시아노사이클로프로필)-N2-[(1S)-2,2,2-트리플루오로-1-(4-메틸페닐)에틸]-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(1H-피라졸-3-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(2-메틸-1,3-옥사졸-4-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(4-피라진-2-일페닐)에틸]-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(2-메틸피리딘-4-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(4-메틸피리딘-3-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(1H-피라졸-4-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-[(1S)-2,2,2-트리플루오로-1-(4-피리딘-4-일페닐)에틸]-L-류신아미드;N2-[(1S)-1-(3'-아세틸-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-[(1S)-2,2,2-트리플루오로-1-(3'-플루오로-4'-메틸-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-((1S)-2,2,2-트리플루오로-1-{5-[4-(1-하이드록시-1-메틸에틸)페닐]피리딘-2-일}에틸)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,3,3,3-펜타플루오로-1-[4'-(1-하이드록시-1-메틸에틸)-1,1'-바이페닐-4-일]프로필}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-[(1S)-2,2,3,3,3-펜타플루오로-1-(4'-메틸-1,1'-바이페닐-4-일)프로필]-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,3,3,3-펜타플루오로-1-[4-(6-메톡시피리딘-3-일)페닐]프로필}-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,3,3,3-펜타플루오로-1-(2'-플루오로-1,1'-바이페닐-4-일)프로필]-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-메톡시-3'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N2-{(1S)-1-[3'-(아미노설포닐)-4'-메톡시-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-N1-(1-시아노사이클로프로필)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(6-메톡시피리딘-3-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,3,3,3-펜타플루오로-1-[4-(5-메틸피리딘-2-일)페닐]프로필}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-((1S)-2,2,2-트리플루오로-1-{4-[5-(메틸설포닐)피리딘-2-일]페닐}에틸)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(5-메틸피리딘-2-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[2'-메틸-4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[5-(1H-피라졸-3-일)피리딘-2-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-[(1S)-2,2,2-트리플루오로-1-(5-퀴놀린-5-일피리딘-2-일)에틸]-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-[(1S)-2,2,2-트리플루오로-1-(5-퀴놀린-6-일피리딘-2-일)에틸]-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2-디플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N2-[(1S)-1-(4'-아세틸-1,1'-바이페닐-4-일)-2,2,3,3,3-펜타플루오로프로필]-N1-(1-시아노사이클로프로필)-L-류신아미드;N2-[(1S)-1-(1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-L-류신아미드;N2-{(1S)-1-[4'-(아미노설포닐)-1,1'-바이페닐-4-일]-2,2,3,3,3-펜타플루오로프로필}-N1-(1-시아노사이클로프로필)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4-(1-에톡시비닐)페닐]-2,2,2-트리플루오로에틸}-L-류신아미드;N2-[(1S)-1-(4-아세틸페닐)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-[(1S)-2,2,2-트리플루오로-1-(4-이소프로필페닐)에틸]-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-[(1S)-2,2,2-트리플루오로-1-페닐에틸]-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(1-하이드록시-1-메틸에틸)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(1-메틸사이클로프로필)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-[(1S)-2,2,2-트리플루오로-1-(2',4',6'-트리메틸-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N2-[(1S)-1-(6-클로로피리딘-3-일)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-L-류신아미드;N2-{(1S)-1-[5-(4-아세틸페닐)피리딘-2-일]-2,2,2-트리플루오로에틸}-N1-(1-시아노사이클로프로필)-L-류신아미드;N2-{(1S)-1-[6-(4-아세틸페닐)피리딘-3-일]-2,2,2-트리플루오로에틸}-N1-(1-시아노사이클로프로필)-L-류신아미드;N2-{(1S)-1-[5-(3-아세틸페닐)피리딘-2-일]-2,2,2-트리플루오로에틸}-N1-(1-시아노사이클로프로필)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-((1S)-2,2,2-트리플루오로-1-{5-[4-(1-하이드록시에틸)페닐]피리딘-2-일}에틸)-L-류신아미드;N2-[(1S)-1-(1,1'-바이페닐-4-일)-2,2,3,3,3-펜타플루오로프로필]-N1-(시아노메틸)-L-류신아미드;N2-[(1S)-1-(4'-아세틸-1,1'-바이페닐-4-일)-2,2,3,3,3-펜타플루오로프로필]-N1-(시아노메틸)-L-류신아미드;N2-[(1S)-1-(1,1'-바이페닐-4-일)-2,2,3,3,3-펜타플루오로프로필]-N1-(1-시아노사이클로프로필)-L-류신아미드;N2-(1-벤질-2,2,2-트리플루오로에틸)-N1-(1-시아노사이클로프로필)-L-류신아미드;N2-[(1S)-1-(4-3급-부틸페닐)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-L-류신아미드;N2-[(1S)-1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-4-메틸-L-류신아미드;N2-[(1S)-1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-4-메틸-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-((1S)-2,2,2-트리플루오로-1-{4-[2-(1H-피라졸-4-일)-1,3-티아졸-4-일]페닐}에틸)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(2-메틸-1,3-티아졸-4-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(2-메틸피리딘-4-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(2-메틸피리딘-3-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(6-메틸피리딘-2-일)페닐]에틸}-L-류신아미드;N2-[(1S)-1-(3'-아세틸-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4-(1H-피라졸-3-일)페닐]에틸}-L-류신아미드;N1-[(1S)-1-시아노에틸]-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-[(1S)-1-시아노-3-(메틸티오)프로필]-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-[(1S)-1-시아노-3-(메틸설포닐)프로필]-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N2-[(1S)-1-(4-브로모페닐)-2,2,3,3,3-펜타플루오로프로필]-N1-(1-시아노사이클로프로필)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,3,3,3-펜타플루오로-1-[4-(6-메톡시피리딘-2-일)페닐]프로필}-L-류신아미드;N2-[(1S)-1-(5-브로모피리딘-2-일)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-((1S)-2,2,2-트리플루오로-1-{5-[4-(메틸설포닐)페닐]피리딘-2-일}에틸)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(1-하이드록시-1-메틸에틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,2-트리플루오로-1-(6'-메틸-3,3'-바이피리딘-6-일)에틸]-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(6-메톡시피리딘-2-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(6-옥소-1,6-디하이드로피리딘-2-일)페닐]에틸}-L-류신아미드;(4S)-N1-(시아노메틸)-5,5,5-트리플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;(4S)-N1-(1-시아노사이클로프로필)-5,5,5-트리플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;(4S)-N1-(시아노메틸)-5,5,5-트리플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸티오)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;(4S)-N1-(1-시아노사이클로프로필)-5,5,5-트리플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸티오)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;(4S)-N2-[(1S)-1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-5,5,5-트리플루오로-L-류신아미드;(4S)-N2-[(1S)-1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-5,5,5-트리플루오로-L-류신아미드;N2-{(1S)-1-[4-(6-아미노피리딘-3-일)페닐]-2,2,2-트리플루오로에틸}-N1-(시아노메틸)-L-류신아미드;N2-[(1S)-1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-4-플루오로-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,3,3,3-펜타플루오로-1-[4-(6-메틸피리딘-3-일)페닐]프로필}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,3,3,3-펜타플루오로-1-[4-(6-메틸피리딘-3-일)페닐]프로필}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(6-메틸피리딘-3-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(1-하이드록시에틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(2,2,2-트리플루오로-1-하이드록시에틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,3,3,3-펜타플루오로-1-[4'-(메틸티오)-1,1'-바이페닐-4-일]프로필}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,3,3,3-펜타플루오로-1-[4'-(1-하이드록시-1-메틸에틸)-1,1'-바이페닐-4-일]프로필}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,3,3,3-펜타플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]프로필}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,3,3,3-펜타플루오로-1-[4-(6-메톡시피리딘-2-일)페닐]프로필}-L-류신아미드;(4R)-N1-(시아노메틸)-5,5,5-트리플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;(4R)-N1-(1-시아노사이클로프로필)-5,5,5-트리플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(시아노메틸)-N2-[(1S)-2,2,3,3,3-펜타플루오로-1-(4'-메틸-1,1'-바이페닐-4-일)프로필]-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,3,3,3-펜타플루오로-1-[4-(1,3-티아졸-2-일)페닐]프로필}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-[(1S)-1-(4-에티닐페닐)-2,2,3,3,3-펜타플루오로프로필]-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-1-[4-(사이클로프로필에티닐)페닐]-2,2,2-트리플루오로에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4-(사이클로프로필에티닐)페닐]-2,2,2-트리플루오로에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(5-메틸-1,3-티아졸-2-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(1,3-티아졸-2-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(5-메틸-1,3-티아졸-2-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4-(사이클로프로필에티닐)페닐]-2,2,3,3,3-펜타플루오로프로필}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(4-메틸-1,3-티아졸-2-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(4-메틸-1,3-티아졸-2-일)페닐]에틸}-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-1-[4-(4,5-디메틸-1,3-티아졸-2-일)페닐]-2,2,2-트리플루오로에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4'-(에틸설포닐)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-[(1S)-2,2,2-트리플루오로-1-(4-피리딘-3-일페닐)에틸]-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-메톡시-3'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N2-[(1S)-1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-L-알라닌아미드;N2-{(1S)-1-[4'-(아미노설포닐)-1,1'-바이페닐-4-일]-2,2,3,3,3-펜타플루오로프로필}-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-((1S)-2,2,3,3,3-펜타플루오로-1-{4'-[(2-하이드록시-2-메틸프로필)설포닐]-1,1'-바이페닐-4-일}프로필)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-알라닌아미드;N1-(시아노메틸)-N2-{(1S)-2,2,3,3,3-펜타플루오로-1-[4'-(이소프로필설포닐)-1,1'-바이페닐-4-일]프로필}-L-류신아미드;N1-(1-시아노-1-메틸에틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-((1S)-2,2,2-트리플루오로-1-{4'-[(2-하이드록시-2-메틸프로필)설포닐]-1,1'-바이페닐-4-일}에틸)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[2'-메틸-4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4'-(에틸설포닐)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-L-류신아미드;N2-{(1S)-1-[4'-(아미노설포닐)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-N1-(1-시아노사이클로프로필)-4-플루오로-L-류신아미드;N1-(시아노메틸)-N2-{(S)-[4'-(메틸설포닐)-1,1'-바이페닐-4-일][4-(트리플루오로메톡시)페닐]메틸}-L-류신아미드;N1-(시아노메틸)-N2-[(S)-[4'-(메틸설포닐)-1,1'-바이페닐-4-일](티엔-2-일)메틸]-L-류신아미드;N1-(시아노메틸)-N2-[(S)-(4'-피페라진-4-이움-1-일-1,1'-바이페닐-4-일)(티엔-2-일)메틸]-L-류신아미드 메탄설포네이트;N1-(시아노메틸)-N2-{(S)-(4-플루오로페닐)[4'-(메틸설포닐)-1,1'-바이페닐-4-일]메틸}-L-류신아미드;N1-(시아노메틸)-N2-{(S)-[4'-(메틸설포닐)-1,1'-바이페닐-4-일][4-(트리플루오로메틸)페닐]메틸}-L-류신아미드;N2-{(S)-(4-클로로페닐)[4'-(메틸설포닐)-1,1'-바이페닐-4-일]메틸}-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N2-[(S)-(4-브로모페닐)(티엔-2-일)메틸]-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-[(S)-[4-(4,4,5,5-테트라메틸라메틸-1,3,2-디옥사보롤란-2-일)페닐](티엔-2-일)메틸]-L-류신아미드;N2-{(R)-(4-브로모페닐)[4-(트리플루오로메톡시)페닐]메틸}-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{(S)-[4-(4,4,5,5-테트라메틸-1,3,2-디옥사보롤란-2-일)페닐][4-(트리플루오로메톡시)페닐]메틸}-L-류신아미드;N2-[(S)-(4-브로모페닐)(2-푸릴)메틸]-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{(S)-2-푸릴[4'-(메틸설포닐)-1,1'-바이페닐-4-일]메틸}-L-류신아미드;N2-[1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-L-노르발린아미드;N2-{(R)-(4-브로모페닐)[4-(트리플루오로메틸)페닐]메틸}-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{1-[4'-(4-사이클로프로필피페라진-1-일)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-L-노르발린아미드;N2-[(R)-(4-브로모페닐)(4-클로로페닐)메틸]-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N2-[(S)-(4-브로모페닐)(3-메틸티엔-2-일)메틸]-N1-(시아노메틸)-L-류신아미드;N2-[(S)-(4-브로모페닐)(티엔-3-일)메틸]-N1-(시아노메틸)-L-류신아미드;N1-(시아노메틸)-N2-{(S)-(2,4-디플루오로페닐)[4'-(메틸설포닐)-1,1'-바이페닐-4-일]메틸}-L-류신아미드;N1-(시아노메틸)-N2-[(S)-[4'-(메틸설포닐)-1,1'-바이페닐-4-일](티엔-3-일)메틸]-L-류신아미드;N1-(시아노메틸)-N2-[(S)-[4'-(메틸설포닐)-1,1'-바이페닐-4-일](3-메틸티엔-2-일)메틸]-L-류신아미드;N1-(시아노메틸)-N2-[(S)-[4'-(4-사이클로프로필피페라진-1-일)-1,1'-바이페닐-4-일](3-메틸티엔-2-일)메틸]-L-류신아미드;N1-(시아노메틸)-N2-[(S)-[4'-(4-사이클로프로필피페라진-1-일)-1,1'-바이페닐-4-일](티엔-3-일)메틸]-L-류신아미드;N2-[1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-5,5,5-트리플루오로-L-노르발린아미드;N1-(시아노메틸)-5,5,5-트리플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N2-[(S)-(4-브로모페닐)(3-메틸티엔-2-일)메틸]-N1-(1-시아노사이클로프로필)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-[(S)-[4'-(메틸설포닐)-1,1'-바이페닐-4-일](3-메틸티엔-2-일)메틸]-L-류신아미드;N1-(시아노메틸)-N2-{(S)-3-푸릴[4'-(메틸설포닐)-1,1'-바이페닐-4-일]메틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N2-[(1S)-1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-L-노르발린아미드;N2-[(S)-(4-브로모페닐)(4-브로모티엔-2-일)메틸]-N1-(시아노메틸)-L-류신아미드;N2-[(S)-(4-브로모페닐)(티엔-3-일)메틸]-N1-(1-시아노사이클로프로필)-L-류신아미드;N1-(시아노메틸)-N2-((S)-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]{4-[4-(메틸설포닐)페닐]티엔-2-일}메틸)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-[(S)-[4'-(메틸설포닐)-1,1'-바이페닐-4-일](티엔-3-일)메틸]-L-류신아미드;N2-{(1S)-1-[4'-(아미노설포닐)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-N1-(1-시아노사이클로프로필)-L-노르발린아미드;N2-[(S)-(4-브로모페닐)(4-브로모티엔-2-일)메틸]-N1-(1-시아노사이클로프로필)-L-류신아미드;N2-[(S)-[4'-(아미노설포닐)-1,1'-바이페닐-4-일](티엔-3-일)메틸]-N1-(1-시아노사이클로프로필)-L-류신아미드;N2-[(S)-[4'-(아미노설포닐)-1,1'-바이페닐-4-일](티엔-3-일)메틸]-N1-(시아노메틸)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-메톡시-3'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(2-메틸피리딘-4-일)페닐]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-5,5,5-트리플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(1H-피라졸-3-일)페닐]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(1-하이드록시-1-메틸에틸)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(5-메틸피리딘-2-일)페닐]에틸}-L-노르발린아미드;2-{[(4-브로모-페닐)-피리딘-4-일-메틸]-아미노}-펜탄산 시아노메틸-아미드;2-{[(4-브로모-페닐)-티아졸-2-일-메틸]-아미노+}-펜탄산 시아노메틸-아미드;(2S)-2-[(S)-1-(4'-아세틸바이페닐-4-일)-2,2,2-트리플루오로에틸아미노]-펜탄산 (1-시아노사이클로프로필)-아미드;(2S)-2-[(S)-1-(2',4'-디플루오로바이페닐-4-일)-2,2,2-트리플루오로에틸아미노]-펜탄산 (1-시아노사이클로프로필)-아미드;(2S)-2-[(S)-1-(3',4'-디플루오로바이페닐-4-일)-2,2,2-트리플루오로에틸아미노]-펜탄산 (1-시아노사이클로프로필)-아미드;(2S)-2-[(S)-1-(3'-클로로-4'-플루오로바이페닐-4-일)-2,2,2-트리플루오로에틸아미노]-펜탄산 (1-시아노-사이클로프로필)-아미드;(2S)-2-[(S)-2,2,2-트리플루오로-1-(4'-메탄설포닐아미노-바이페닐-4-일)-에틸아미노]-펜탄산 (1-시아노-사이클로프로필)-아미드;(2S)-2-{(S)-[(4-브로모-페닐)-티아졸-2-일-메틸]-아미노}-4-메틸펜탄산 시아노메틸-아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-클로로-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-클로로-3'-메틸-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-클로로-2'-메틸-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;(2S)-2-{(S)-2,2,2-트리플루오로-1-[4-(1H-인돌-5-일)-페닐]-에틸아미노}-펜탄산 (1-시아노-사이클로프로필)-아미드;(2S)-2-[(S)-2,2,2-트리플루오로-1-(3'-메탄설포닐아미노-바이페닐-4-일)-에틸아미노]-펜탄산 (1-시아노-사이클로프로필)-아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-플루오로-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-플루오로-3'-메틸-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[3'-플루오로-4'-메틸-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-트리플루오로메톡시-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;(2S)-2-[(S)-2,2,2-트리플루오로-1-(4'-메틸바이페닐-4-일)-에틸아미노]-펜탄산 (1-시아노사이클로프로필)-아미드;(2S)-2-[(S)-1-(4'-시아노바이페닐-4-일)-2,2,2-트리플루오로에틸아미노]-펜탄산 (1-시아노사이클로프로필)-아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-메톡시-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4-(벤조[1,3]디옥소l-5-일)페닐]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메톡시카보닐)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;(2S)-2-{(S)-[(4-브로모페닐)-티아졸-2-일-메틸]-아미노}-4-메틸펜탄산 (1-시아노사이클로프로필)-아미드;(2S)-2-{(S)-[(4'-메탄설포닐-바이페닐-4-일)-티아졸-2-일-메틸]-아미노}-4-메틸-펜탄산 시아노메틸-아미드;(2S)-2-[(S)-2,2,2-트리플루오로-1-(4'-트리플루오로메틸-바이페닐-4-일)-에틸아미노]-펜탄산 (1-시아노-사이클로프로필)-아미드;(2S)-2-[(S)-2,2,2-트리플루오로-1-(2'-트리플루오로메틸-바이페닐-4-일)-에틸아미노]-펜탄산 (1-시아노-사이클로프로필)-아미드;(2S)-2-{(S)-[(2',4'-디플루오로바이페닐-4-일)-티아졸-2-일-메틸]-아미노}-4-메틸펜탄산 (1-시아노사이클로프로필)-아미드;(2S)-2-{(S)-[(4'-메탄설포닐바이페닐-4-일)-티아졸-2-일-메틸]-아미노}-4-메틸펜탄산 (1-시아노사이클로프로필)-아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4-(1-옥시도-2,3-디하이드로-1-벤조티엔-5-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4-(1,1-디옥시도-2,3-디하이드로-1-벤조티엔-5-일)페닐]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4-(1,1-디옥시도-2,3-디하이드로-1,2-벤즈이소티아졸-5-일)페닐]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설피닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4-(1,1-디옥시도-3-옥소-2,3-디하이드로-1,2-벤즈이소티아졸-5-일)페닐]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[2'-(1-하이드록시-1-메틸에틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4,4-디플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(시아노메틸)-4,4-디플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(시아노메틸)-4-플루오로-N2-{(1S)-2,2,2-트리클로로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리클로로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4,4-디플루오로-N2-{(1S)-2,2,2-트리클로로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(시아노메틸)-4,4-디플루오로-N2-{(1S)-2,2,2-트리클로로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;(2S)-N-(시아노메틸)-4,4-디플루오로-2-({(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}아미노)부탄아미드;(2S)-N-(1-시아노사이클로프로필)-4,4-디플루오로-2-({(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}아미노)부탄아미드;(2S)-N-(1-시아노사이클로프로필)-4,4-디플루오로-2-({(1S)-2,2,2-트리클로로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}아미노)부탄아미드;(2S)-N-(시아노메틸)-4,4-디플루오로-2-({(1S)-2,2,2-트리클로로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}아미노)부탄아미드;(2S)-4,4-디클로로-N-(시아노메틸)-2-({(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}아미노)부탄아미드;(2S)-4,4-디클로로-N-(1-시아노사이클로프로필)-2-({(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}아미노)부탄아미드;(2S)-4,4-디클로로-N-(1-시아노사이클로프로필)-2-({(1S)-2,2,2-트리클로로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}아미노)부탄아미드;(2S)-4,4-디클로로-N-(시아노메틸)-2-({(1S)-2,2,2-트리클로로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}아미노)부탄아미드;N2-[(1S)-1-(1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[3'-(1-하이드록시에틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-[(1S)-2,2,2-트리플루오로-1-(4'-메틸-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[3'-(1-하이드록시-1-메틸에틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N2-[(1S)-1-(4'-아세틸-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-4-플루오로-L-류신아미드;N2-[(1S)-1-(2'-아세틸-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(1-하이드록시에틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[2'-(1-하이드록시에틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(1-하이드록시-1-메틸에틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[2'-(1-하이드록시-1-메틸에틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-((1S)-2,2,2-트리플루오로-1-{5-[4-(메틸설포닐)페닐]피리딘-2-일}에틸)-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-((1S)-2,2,2-트리플루오로-1-{6-[4-(메틸설포닐)페닐]피리딘-3-일}에틸)-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-[(1S)-2,2,2-트리플루오로-1-(4-{6-[(메틸설포닐)아미노]피리딘-3-일}페닐)에틸]-L-류신아미드;N1-(시아노메틸)-4-플루오로-N2-[(1S)-2,2,2-트리플루오로-1-(4-{6-[(메틸설포닐)아미노]피리딘-3-일}페닐)에틸]-L-류신아미드;N1-(1-시아노부틸)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노-2-사이클로프로필에틸)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노-2-피리딘-3-일에틸)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노-3-하이드록시-3-메틸부틸)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4-(1-옥소-1,3-디하이드로-2-벤조푸란-5-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4-(3,3-디메틸-1-옥소-1,3-디하이드로-2-벤조푸란-5-일)페닐]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4-(3,3-디에틸-1-옥소-1,3-디하이이드로-2-벤조푸란-5-일)페닐]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4-(3-옥소-1,3-디하이드로-2-벤조푸란-5-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4-(1,1-디메틸-3-옥소-1,3-디하이드로-2-벤조푸란-5-일)페닐]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4-(1,1-디에틸-3-옥소-1,3-디하이드로-2-벤조푸란-5-일)페닐]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(3-옥소-1,3-디하이드로-2-벤조푸란-5-일)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4'-(1,1-디메틸-3-옥소-1,3-디하이드로-2-벤조푸란-5-일)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4'-(1,1-디에틸-3-옥소-1,3-디하이드로-2-벤조푸란-5-일)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(1-옥소-1,3-디하이드로-2-벤조푸란-5-일)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4'-(3,3-디메틸-1-옥소-1,3-디하이드로-2-벤조푸란-5-일)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4'-(3,3-디에틸-1-옥소-1,3-디하이드로-2-벤조푸란-5-일)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4-(5-옥소-2,5-디하이드로푸란-3-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4-(2,2-디메틸-5-옥소-2,5-디하이드로푸란-3-일)페닐]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4-(2,2-디에틸-5-옥소-2,5-디하이드로푸란-3-일)페닐]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4-(2-옥소-2,5-디하이드로푸란-3-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4-(5,5-디메틸-2-옥소-2,5-디하이드로푸란-3-일)페닐]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4-(5,5-디에틸-2-옥소-2,5-디하이드로푸란-3-일)페닐]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4-(5-옥소-4-옥사스피로[2.4]헵트-6-엔-7-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4-(6-옥소-5-옥사스피로[3.4]옥트-7-엔-8-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4-(5-옥소-4-옥사스피로[2.4]헵트-6-엔-6-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4-(6-옥소-5-옥사스피로[3.4]옥트-7-엔-7-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-[(1S)-2,2,2-트리플루오로-1-(4-퀴놀린-6-일페닐)에틸]-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설피닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N2-[(1S)-1-(4'-아세틸-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-[(1S)-2,2,2-트리플루오로-1-(4-퀴놀린-6-일페닐)에틸]-L-류신아미드;N2-[(1S)-1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-4,4-디플루오로-L-노르발린아미드;N1-(1-시아노사이클로프로필)-4,4-디플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸티오)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-4,4-디플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-[(1S)-1-시아노-3-(메틸설포닐)프로필]-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-(4-퀴놀린-6-일페닐)에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설피닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(1-하이드록시에틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N2-[(1S)-1-(4'-아세틸-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N'-(1-시아노사이클로프로필)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-(4-퀴놀린-6-일페닐)에틸]-L-류신아미드;N2-[(1S)-1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-4,4-디플루오로-L-노르발린아미드;N1-(1-시아노사이클로프로필)-4,4-디플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸티오)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-4,4-디플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-((1S)-2,2,2-트리플루오로-1-{4-[5-메틸-6-(메틸설포닐)피리딘-3-일]페닐}에틸)-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-((1S)-2,2,2-트리플루오로-1-{4-[6-(1-하이드록시-1-메틸에틸)-5-메틸피리딘-3-일]페닐}에틸)-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-[(1S)-2,2,2-트리플루오로-1-(4'-플루오로-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[3'-메틸-4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4-(6-메틸피리딘-3-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸티오)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(1-하이드록시-1-메틸에틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4-(2-메틸퀴놀린-7-일)페닐]에틸}-L-류신아미드;N2-[(1S)-1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-4,4-디플루오로-L-노르발린아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-((1S)-2,2,2-트리플루오로-1-4'-[(1S)-1-하이드록시에틸]-1,1'-바이페닐-4-일에틸)-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-((1S)-2,2,2-트리플루오로-1-4'-[(1R)-1-하이드록시에틸]-1,1'-바이페닐-4-일에틸)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(트리플루오로아세틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[5-(2-나프틸)피리딘-2-일]에틸}-L-류신아미드;N1-(시아노메틸)-4,4-디플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸티오)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(시아노메틸)-4,4-디플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4-(5-메틸-1,3-티아졸-2-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4-(1,1-디옥시도-3-옥소-2,3-디하이드로-1,2-벤즈이소티아졸-5-일)페닐]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N2-[(4-브로모페닐)(페닐)메틸]-N1-(1-시아노사이클로프로필)-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-[(1S)-2,2,2-트리플루오로-1-(4'-메틸-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N2-[(1S)-1-(1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-4-플루오로-L-류신아미드;N2-{(1S)-1-[4-(5-클로로피리딘-2-일)페닐]-2,2,2-트리플루오로에틸}-N1-(1-시아노사이클로프로필)-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-[(1S)-2,2,2-트리플루오로-1-(4-피리딘-4-일페닐)에틸]-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-((1S)-2,2,2-트리플루오로-1-{4'-[(메틸설포닐)아미노]-1,1'-바이페닐-4-일}에틸)-L-류신아미드;N2-[(1S)-1-(4-브로모페닐)-2,2-디플루오로에틸]-N1-(1-시아노사이클로프로필)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2-디플루오로-1-[4'-(메틸티오)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-[(1S)-2,2,2-트리플루오로-1-(4-피리미딘-5-일페닐)에틸]-L-류신아미드;N2-[(1S)-1-(4'-아세틸-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[3'-(1-하이드록시에틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N2-[(1S)-1-(4'-아세틸-1,1'-바이페닐-4-일)-2,2-디플루오로에틸]-N1-(1-시아노사이클로프로필)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4-(3,5-디메틸이속사졸-4-일)페닐]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N1-[(1S)-1-시아노-3-(메틸설포닐)프로필]-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-[(1S)-2,2,2-트리플루오로-1-(4-퀴놀린-6-일페닐)에틸]-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설피닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(1-하이드록시에틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N2-[(1S)-1-(4'-아세틸-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-[(1S)-2,2,2-트리플루오로-1-(4-퀴놀린-6-일페닐)에틸]-L-류신아미드;N2-[(1S)-1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-4,4-디플루오로-L-노르발린아미드;N1-(1-시아노사이클로프로필)-4,4-디플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸티오)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-4,4-디플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-((1S)-2,2,2-트리플루오로-1-4-[5-메틸-6-(메틸설포닐)피리딘-3-일]페닐에틸)-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-((1S)-2,2,2-트리플루오로-1-4-[6-(1-하이드록시-1-메틸에틸)-5-메틸피리딘-3-일]페닐에틸)-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-[(1S)-2,2,2-트리플루오로-1-(4'-플루오로-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[3'-메틸-4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4-(6-메틸피리딘-3-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸티오)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(1-하이드록시-1-메틸에틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4-(2-메틸퀴놀린-7-일)페닐]에틸}-L-류신아미드;N2-[(1S)-1-(4-브로모페닐)-2,2,2-트리플루오로에틸]-N1-(시아노메틸)-4,4-디플루오로-L-노르발린아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-((1S)-2,2,2-트리플루오로-1-{4'-[(1S)-1-하이드록시에틸]-1,1'-바이페닐-4-일}에틸)-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-((1S)-2,2,2-트리플루오로-1-{4'-[(1R)-1-하이드록시에틸]-1,1'-바이페닐-4-일}에틸)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(트리플루오로아세틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2,2-트리플루오로-1-[5-(2-나프틸)피리딘-2-일]에틸}-L-류신아미드;N1-(시아노메틸)-4,4-디플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸티오)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(시아노메틸)-4,4-디플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-노르발린아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4-(5-메틸-1,3-티아졸-2-일)페닐]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4-(1,1-디옥시도-3-옥소-2,3-디하이드로-1,2-벤즈이소티아졸-5-일)페닐]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드;N2-[(4-브로모페닐)(페닐)메틸]-N1-(1-시아노사이클로프로필)-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-[(1S)-2,2,2-트리플루오로-1-(4'-메틸-1,1'-바이페닐-4-일)에틸]-L-류신아미드;N2-[(1S)-1-(1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-4-플루오로-L-류신아미드;N2-{(1S)-1-[4-(5-클로로피리딘-2-일)페닐]-2,2,2-트리플루오로에틸}-N1-(1-시아노사이클로프로필)-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-[(1S)-2,2,2-트리플루오로-1-(4-피리딘-4-일페닐)에틸]-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-((1S)-2,2,2-트리플루오로-1-{4'-[(메틸설포닐)아미노]-1,1'-바이페닐-4-일}에틸)-L-류신아미드;N2-[(1S)-1-(4-브로모페닐)-2,2-디플루오로에틸]-N1-(1-시아노사이클로프로필)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-2,2-디플루오로-1-[4'-(메틸티오)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-[(1S)-2,2,2-트리플루오로-1-(4-피리미딘-5-일페닐)에틸]-L-류신아미드;N2-[(1S)-1-(4'-아세틸-1,1'-바이페닐-4-일)-2,2,2-트리플루오로에틸]-N1-(1-시아노사이클로프로필)-4-플루오로-L-류신아미드;N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[3'-(1-하이드록시에틸)-1,1'-바이페닐-4-일]에틸}-L-류신아미드;N2-[(1S)-1-(4'-아세틸-1,1'-바이페닐-4-일)-2,2-디플루오로에틸]-N1-(1-시아노사이클로프로필)-L-류신아미드;N1-(1-시아노사이클로프로필)-N2-{(1S)-1-[4-(3,5-디메틸이속사졸-4-일)페닐]-2,2,2-트리플루오로에틸}-4-플루오로-L-류신아미드로부터 선택된, 화학식 I의 화합물, 또는 이의 약제학적으로 허용되는 염, 입체이성체 또는 N-옥사이드 유도체.
- N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드 또는 약제학적으로 허용되는 이의 염.
- N1-(1-시아노사이클로프로필)-4-플루오로-N2-{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설피닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드 또는 약제학적으로 허용되는 이의 염.
- N1(시아노메틸)-N2{(1S)-2,2,2-트리플루오로-1-[4'-(메틸설포닐)-1,1'-바이페닐-4-일]에틸}-L-류신아미드 또는 약제학적으로 허용되는 이의 염.
- N2{(1S)-1-[4'-(아미노설포닐)-1,1'-바이페닐-4-일]-2,2,2-트리플루오로에틸-N1(시아노메틸)-L-류신아미드 또는 약제학적으로 허용되는 이의 염.
- 삭제
- 삭제
- 제1항에 따른 화합물과 약제학적으로 허용되는 담체를 배합하는 것을 포함하는 약제학적 조성물의 제조방법.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36181802P | 2002-03-05 | 2002-03-05 | |
US60/361,818 | 2002-03-05 | ||
US40870402P | 2002-09-06 | 2002-09-06 | |
US60/408,704 | 2002-09-06 | ||
PCT/US2003/006147 WO2003075836A2 (en) | 2002-03-05 | 2003-02-28 | Cathepsin cysteine protease inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040095262A KR20040095262A (ko) | 2004-11-12 |
KR100975784B1 true KR100975784B1 (ko) | 2010-08-17 |
Family
ID=27807943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047013833A KR100975784B1 (ko) | 2002-03-05 | 2003-02-28 | 카텝신 시스테인 프로테아제 억제제 |
Country Status (28)
Country | Link |
---|---|
US (6) | US20030232863A1 (ko) |
EP (1) | EP1482924B1 (ko) |
JP (2) | JP4201716B2 (ko) |
KR (1) | KR100975784B1 (ko) |
CN (1) | CN100430052C (ko) |
AT (1) | ATE395911T1 (ko) |
AU (1) | AU2003219953B8 (ko) |
BR (1) | BRPI0308208B8 (ko) |
CA (1) | CA2477657C (ko) |
CL (1) | CL2003001743A1 (ko) |
CY (1) | CY1111130T1 (ko) |
DE (1) | DE60321141D1 (ko) |
DK (1) | DK1482924T3 (ko) |
EC (1) | ECSP045261A (ko) |
ES (1) | ES2305452T3 (ko) |
HK (1) | HK1080375A1 (ko) |
HR (1) | HRP20040800B1 (ko) |
IL (2) | IL163748A0 (ko) |
IS (1) | IS2549B (ko) |
MA (1) | MA27295A1 (ko) |
MX (1) | MXPA04008621A (ko) |
NO (1) | NO335099B1 (ko) |
NZ (1) | NZ534583A (ko) |
PL (1) | PL215865B1 (ko) |
PT (1) | PT1482924E (ko) |
RU (1) | RU2312861C2 (ko) |
SI (1) | SI1482924T1 (ko) |
WO (1) | WO2003075836A2 (ko) |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9937531B2 (en) | 2009-03-10 | 2018-04-10 | Bookit Oy Ajanvarauspalvelu | Method and system for delivery of goods |
JP4865989B2 (ja) | 2002-02-01 | 2012-02-01 | ベンド・リサーチ・インコーポレーテッド | 改良された噴霧乾燥装置を使用する均質な噴霧乾燥された固体の非晶質薬物分散物を製造する方法 |
PL215865B1 (pl) * | 2002-03-05 | 2014-02-28 | Axys Pharmaceuticals | Zwiazek, kompozycja farmaceutyczna i zastosowanie zwiazku |
US7745154B2 (en) * | 2002-03-19 | 2010-06-29 | Kowa Co., Ltd. | Preventives/remedies for myeloma tumor and method of diagnosing the same |
EP1631548B1 (en) * | 2003-04-24 | 2009-10-28 | Merck & Co., Inc. | Inhibitors of akt activity |
AU2004266740B2 (en) * | 2003-08-21 | 2010-08-26 | Merck Frosst Canada Ltd | Cathepsin cysteine protease inhibitors |
AU2004268707A1 (en) * | 2003-08-27 | 2005-03-10 | Merck Frosst Canada Ltd | Cathepsin inhibitors |
EA011855B1 (ru) * | 2003-09-18 | 2009-06-30 | Вайробей, Инк. | Соединения, содержащие галоидалкил, как ингибиторы цистеиновых протеаз |
JP4769192B2 (ja) * | 2003-10-24 | 2011-09-07 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | カテプシン阻害剤としての新規な化合物及び組成物 |
CA2548600A1 (en) * | 2003-12-12 | 2005-06-23 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
AU2005203820A1 (en) * | 2004-01-08 | 2005-07-21 | Merck Frosst Canada Ltd | Cathepsin cysteine protease inhibitors |
US7429674B2 (en) | 2004-04-14 | 2008-09-30 | Merck & Co. Inc.. | Process for preparing fluoroleucine alkyl esters |
CA2575139A1 (en) * | 2004-08-04 | 2006-02-16 | Merck & Co., Inc. | Diastereoselective reductive amination process |
BRPI0515470A (pt) * | 2004-09-17 | 2008-07-22 | Schering Ag | processos e intermediários para preparação de inibidores de cisteìna protease |
TW200619206A (en) * | 2004-09-29 | 2006-06-16 | Anormed Inc | Chemokine-binding heterocyclic compound salts, and methods of use thereof |
AR055283A1 (es) * | 2004-11-23 | 2007-08-15 | Merck Frosst Canada Ltd | Inhibidores de cisteinproteasa de catepsina |
EP1817275A1 (en) | 2004-12-01 | 2007-08-15 | Schering Aktiengesellschaft | Haloalkyl containing compounds as cysteine protease inhibitors |
WO2006060810A1 (en) | 2004-12-02 | 2006-06-08 | Schering Aktiengesellschaft | Sulfonamide compounds as cysteine protease inhibitors |
EP1841730A4 (en) * | 2005-01-19 | 2010-10-27 | Merck Frosst Canada Ltd | CATHEPSIN K INHIBITORS AND ATHEROSCLEROSIS |
WO2006076796A1 (en) * | 2005-01-19 | 2006-07-27 | Merck Frosst Canada Ltd. | Cathepsin k inhibitors and obesity |
DK1855674T3 (da) * | 2005-03-02 | 2014-10-20 | Merck Sharp & Dohme | Sammensætning til hæmning af cathepsin k |
WO2006093467A1 (en) * | 2005-03-02 | 2006-09-08 | Agency For Science, Technology And Research | Conjugated organic molecules for molecular electronic devices |
KR101447897B1 (ko) | 2005-03-21 | 2014-10-07 | 비로베이, 인코포레이티드 | 시스테인 단백질분해효소 억제제로서의 알파 케토아미드화합물 |
WO2006102535A2 (en) * | 2005-03-22 | 2006-09-28 | Celera Genomics | Sulfonyl containing compounds as cysteine protease inhibitors |
JP2008545720A (ja) | 2005-06-02 | 2008-12-18 | メルク フロスト カナダ リミテツド | カテプシン阻害剤としてのフルオロアルキルアミン誘導体 |
NZ565141A (en) | 2005-07-19 | 2010-12-24 | Daiichi Sankyo Co Ltd | Substituted propanamide derivative and pharmaceutical composition containing the same |
BRPI0614169A2 (pt) * | 2005-07-26 | 2016-11-22 | Merck Frosst Canada Ltd | método para tratar uma doença parasítica, e, composição farmacêutica |
MY156425A (en) * | 2006-06-01 | 2016-02-26 | Sanofi Aventis | Spirocyclic nitriles as protease inhibitors |
US7622593B2 (en) * | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7893112B2 (en) * | 2006-10-04 | 2011-02-22 | Virobay, Inc. | Di-fluoro containing compounds as cysteine protease inhibitors |
CA2664878A1 (en) * | 2006-10-04 | 2008-04-10 | Virobay, Inc. | Di-fluoro containing compounds as cysteine protease inhibitors |
TWI405571B (zh) * | 2006-12-29 | 2013-08-21 | Abbott Gmbh & Co Kg | 羰醯胺化合物及其作為鈣蛋白酶(calpain)抑制劑之用途 |
EP2132173B1 (en) | 2007-02-26 | 2015-10-07 | Merck Sharp & Dohme Corp. | Formulations for cathepsin k inhibitors |
CN101668736B (zh) * | 2007-04-02 | 2013-06-12 | 默克弗罗斯特加拿大有限公司 | 用于制备组织蛋白酶k抑制剂的酰胺化反应 |
WO2008149971A1 (ja) | 2007-06-08 | 2008-12-11 | Kyoto University | 脳動脈瘤の治療または予防薬 |
EP2216047A4 (en) | 2007-10-24 | 2011-12-28 | Nat Univ Corp Tokyo Med & Dent | REGULATOR FOR SIGNALING THE TOLL LIKE RECEPTOR WITH A CATHEPSIN INHIBITOR AS AN ACTIVE SUBSTANCE |
JP5511676B2 (ja) * | 2007-11-29 | 2014-06-04 | メルク カナダ インコーポレイテッド | 寄生虫疾患を治療するためのシステインプロテアーゼ阻害剤 |
WO2009096198A1 (ja) * | 2008-02-01 | 2009-08-06 | Pharma Ip Limited Liability Intermediary Corporations | 新規ビアリール誘導体 |
WO2009123623A1 (en) * | 2008-04-01 | 2009-10-08 | Virobay, Inc. | Di-fluoro containing compounds as cysteine protease inhibitors |
WO2009125861A1 (ja) * | 2008-04-09 | 2009-10-15 | 帝人ファーマ株式会社 | システインプロテアーゼ阻害剤 |
US20110065800A1 (en) * | 2008-05-14 | 2011-03-17 | Haihong Fan | Formulations for cathepsin k inhibitors |
CA2758210C (en) * | 2009-04-20 | 2017-08-29 | F. Hoffmann-La Roche Ag | Proline derivatives as cathepsin inhibitors |
US8324417B2 (en) * | 2009-08-19 | 2012-12-04 | Virobay, Inc. | Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof |
US9051304B2 (en) * | 2009-12-22 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Carboxamide compounds and their use as calpain inhibitors V |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
US8791162B2 (en) | 2011-02-14 | 2014-07-29 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
US20130331597A1 (en) * | 2011-03-02 | 2013-12-12 | Guy Humphrey | Amidation process |
WO2012151319A1 (en) | 2011-05-02 | 2012-11-08 | Virobay, Inc. | Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain |
US9943522B2 (en) | 2011-05-16 | 2018-04-17 | Bayer Intellectual Property Gmbh | Use of cathepsin K inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure |
US10023862B2 (en) | 2012-01-09 | 2018-07-17 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat beta-catenin-related diseases |
CN107383009B (zh) | 2012-06-13 | 2020-06-09 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
SG11201505697VA (en) | 2013-02-19 | 2015-09-29 | Novartis Ag | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
PT2968316T (pt) | 2013-03-13 | 2019-10-29 | Forma Therapeutics Inc | Derivados de 2-hidroxi-1-{4-[(4-fenilfenil)carbonil]piperazin-1-il}etano-1-ona e compostos relacionados como inibidores da sintase de ácidos gordos (fasn) para o tratamento do cancro |
SG11201508328PA (en) | 2013-04-19 | 2015-11-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
EP2996678A1 (en) | 2013-05-16 | 2016-03-23 | Sandoz AG | Tablet with increased drug load of odanacatib |
EP2808012A1 (en) | 2013-05-29 | 2014-12-03 | ratiopharm GmbH | Method for producing dosage form comprising odanacatib |
US9562042B2 (en) | 2013-06-14 | 2017-02-07 | Seikagaku Corporation | α-oxoacyl amino-caprolactam |
JP6336973B2 (ja) | 2013-06-14 | 2018-06-06 | 生化学工業株式会社 | α−オキソアシルアミノカプロラクタム誘導体 |
US20160166529A1 (en) * | 2013-07-11 | 2016-06-16 | Merck Sharp & Dohme Corp. | Formulations for Cathepsin K Inhibitors with Vitamin D |
CA2923272A1 (en) * | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
WO2015107493A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
JP6473457B2 (ja) | 2014-01-17 | 2019-02-20 | ノバルティス アーゲー | Shp2の活性を阻害するための1−(トリアジン−3−イル/ピリダジン−3−イル)−ピペリジン/ピペラジン誘導体およびその組成物 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
CZ2014941A3 (cs) | 2014-12-19 | 2016-06-29 | Zentiva, K.S. | Příprava vysoce čistého intermediátu pro syntézu Odanacatibu |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
CN107438607B (zh) | 2015-02-20 | 2021-02-05 | 因赛特公司 | 作为fgfr抑制剂的双环杂环 |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016151499A1 (en) | 2015-03-25 | 2016-09-29 | Novartis Ag | Formylated n-heterocyclic derivatives as fgfr4 inhibitors |
ES2824576T3 (es) | 2015-06-19 | 2021-05-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
ES2741746T3 (es) | 2015-06-19 | 2020-02-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
ES2805232T3 (es) | 2015-06-19 | 2021-02-11 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
US10494364B2 (en) | 2015-08-29 | 2019-12-03 | Sunshin Lake Pharma Co., Ltd | Cathepsin K inhibitors and application thereof |
EP3380455A1 (en) * | 2015-11-26 | 2018-10-03 | H. Hoffnabb-La Roche Ag | Trypanosomes inhibitors |
CN106866502B (zh) * | 2015-12-10 | 2020-10-09 | 广东东阳光药业有限公司 | 组织蛋白酶k抑制剂及其用途 |
ES2849560T3 (es) | 2016-05-04 | 2021-08-19 | Genoscience Pharma Sas | Derivados de 2,4-diamino-quinolina sustituidos para su uso en el tratamiento de enfermedades proliferativas |
KR102457146B1 (ko) | 2016-06-14 | 2022-10-19 | 노파르티스 아게 | Shp2의 활성을 억제하기 위한 화합물 및 조성물 |
CA3050224A1 (en) * | 2017-01-24 | 2018-08-02 | Astellas Pharma Inc. | Phenyldifluoromethyl-substituted prolinamide compound |
KR101916396B1 (ko) | 2017-02-20 | 2018-11-08 | 서울대학교 산학협력단 | 항암제 또는 항균제로 사용될 수 있는 단백질분해효소 저해제 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
CN111201223B (zh) | 2017-09-11 | 2024-07-09 | 克鲁松制药公司 | SHP2的八氢环戊二烯并[c]吡咯别构抑制剂 |
NL2020021B1 (en) * | 2017-12-05 | 2019-06-13 | Academisch Ziekenhuis Leiden | Cathepsin inhibitors |
WO2019112426A1 (en) * | 2017-12-05 | 2019-06-13 | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) | Cathepsin inhibitors |
CA3093546A1 (en) | 2018-03-28 | 2019-10-03 | Hanlim Pharmaceutical Co., Ltd. | 2-cyanopyrimidin-4-yl carbamate or urea derivative or salt thereof, and pharmaceutical composition including same |
AU2019262195B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
CA3099116A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
SG11202102679QA (en) | 2018-09-18 | 2021-04-29 | Nikang Therapeutics Inc | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
EP3856726A1 (en) | 2018-09-25 | 2021-08-04 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use |
CN113164776A (zh) | 2018-09-25 | 2021-07-23 | 黑钻治疗公司 | 酪氨酸激酶抑制剂组合物、其制备方法和使用方法 |
MX2021003459A (es) | 2018-09-29 | 2021-06-18 | Novartis Ag | Proceso de fabricacion de un compuesto para la inhibicion de la actividad de shp2. |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
CN113382633A (zh) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式 |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2020201572A1 (en) | 2019-04-05 | 2020-10-08 | Université De Bretagne Occidentale | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021030711A1 (en) | 2019-08-15 | 2021-02-18 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
JP2022552324A (ja) | 2019-10-14 | 2022-12-15 | インサイト・コーポレイション | Fgfr阻害剤としての二環式複素環 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021195206A1 (en) | 2020-03-24 | 2021-09-30 | Black Diamond Therapeutics, Inc. | Polymorphic forms and related uses |
EP4204020A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
CN114539111A (zh) * | 2020-11-19 | 2022-05-27 | 深圳信立泰药业股份有限公司 | 奥当卡替的盐及其制备方法和医药用途 |
EP4267575A1 (en) | 2020-12-22 | 2023-11-01 | Nikang Therapeutics, Inc. | Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway |
MX2023008296A (es) | 2021-01-13 | 2023-09-29 | Monte Rosa Therapeutics Inc | Compuestos de isoindolinona. |
WO2022170052A1 (en) | 2021-02-05 | 2022-08-11 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof |
US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
EP4323349A1 (en) | 2021-04-14 | 2024-02-21 | Monte Rosa Therapeutics AG | Isoindolinone amide compounds useful to treat diseases associated with gspt1 |
WO2022219407A1 (en) | 2021-04-14 | 2022-10-20 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Fgfr阻害剤としての三環式ヘテロ環 |
CN117980310A (zh) | 2021-07-14 | 2024-05-03 | 尼坎治疗公司 | 作为kras抑制剂的亚烷基衍生物 |
US20230303509A1 (en) | 2022-03-28 | 2023-09-28 | Nikang Therapeutics, Inc. | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors |
WO2023240024A1 (en) | 2022-06-08 | 2023-12-14 | Nikang Therapeutics, Inc. | Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors |
WO2024102849A1 (en) | 2022-11-11 | 2024-05-16 | Nikang Therapeutics, Inc. | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002069901A2 (en) * | 2001-03-02 | 2002-09-12 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR200001189T2 (tr) * | 1997-11-05 | 2000-09-21 | Novartis Ag. | Dipeptid nitriller. |
AU2560300A (en) | 1999-02-20 | 2000-09-04 | Astrazeneca Ab | Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsins |
CA2368148A1 (en) * | 1999-03-15 | 2000-09-21 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions as protease inhibitors |
IL148630A0 (en) * | 1999-09-16 | 2002-09-12 | Axys Pharm Inc | Compounds and pharmaceutical compositions for inhibiting cathepsin s |
GB0003111D0 (en) * | 2000-02-10 | 2000-03-29 | Novartis Ag | Organic compounds |
DE60113406T2 (de) * | 2000-05-15 | 2006-06-29 | Novartis Ag | N-substituierte peptidylnitrile als cystein-cathepsin-inhibitoren |
WO2003017598A1 (en) * | 2001-08-15 | 2003-02-27 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Scsi-to-ip cache storage device and method |
JP4343690B2 (ja) * | 2001-11-13 | 2009-10-14 | メルク フロスト カナダ リミテツド | プロテアーゼ阻害薬としてのシアノアルキルアミノ誘導体 |
PL215865B1 (pl) * | 2002-03-05 | 2014-02-28 | Axys Pharmaceuticals | Zwiazek, kompozycja farmaceutyczna i zastosowanie zwiazku |
EA011855B1 (ru) * | 2003-09-18 | 2009-06-30 | Вайробей, Инк. | Соединения, содержащие галоидалкил, как ингибиторы цистеиновых протеаз |
AR055283A1 (es) * | 2004-11-23 | 2007-08-15 | Merck Frosst Canada Ltd | Inhibidores de cisteinproteasa de catepsina |
JP2008545720A (ja) * | 2005-06-02 | 2008-12-18 | メルク フロスト カナダ リミテツド | カテプシン阻害剤としてのフルオロアルキルアミン誘導体 |
-
2003
- 2003-02-28 PL PL372204A patent/PL215865B1/pl unknown
- 2003-02-28 SI SI200331271T patent/SI1482924T1/sl unknown
- 2003-02-28 CA CA2477657A patent/CA2477657C/en not_active Expired - Lifetime
- 2003-02-28 AU AU2003219953A patent/AU2003219953B8/en not_active Ceased
- 2003-02-28 KR KR1020047013833A patent/KR100975784B1/ko active IP Right Grant
- 2003-02-28 BR BRPI0308208A patent/BRPI0308208B8/pt not_active IP Right Cessation
- 2003-02-28 US US10/377,377 patent/US20030232863A1/en not_active Abandoned
- 2003-02-28 ES ES03716238T patent/ES2305452T3/es not_active Expired - Lifetime
- 2003-02-28 NZ NZ534583A patent/NZ534583A/en not_active IP Right Cessation
- 2003-02-28 RU RU2004129587/04A patent/RU2312861C2/ru active
- 2003-02-28 MX MXPA04008621A patent/MXPA04008621A/es active IP Right Grant
- 2003-02-28 EP EP03716238A patent/EP1482924B1/en not_active Expired - Lifetime
- 2003-02-28 DE DE60321141T patent/DE60321141D1/de not_active Expired - Lifetime
- 2003-02-28 PT PT03716238T patent/PT1482924E/pt unknown
- 2003-02-28 US US10/505,796 patent/US7375134B2/en active Active
- 2003-02-28 WO PCT/US2003/006147 patent/WO2003075836A2/en active Application Filing
- 2003-02-28 DK DK03716238T patent/DK1482924T3/da active
- 2003-02-28 AT AT03716238T patent/ATE395911T1/de active
- 2003-02-28 CN CNB038051818A patent/CN100430052C/zh not_active Expired - Fee Related
- 2003-02-28 JP JP2003574112A patent/JP4201716B2/ja not_active Expired - Fee Related
- 2003-02-28 IL IL16374803A patent/IL163748A0/xx unknown
- 2003-08-27 CL CL200301743A patent/CL2003001743A1/es unknown
-
2004
- 2004-08-12 IS IS7400A patent/IS2549B/is unknown
- 2004-08-17 MA MA27826A patent/MA27295A1/fr unknown
- 2004-08-26 IL IL163748A patent/IL163748A/en not_active IP Right Cessation
- 2004-09-01 EC EC2004005261A patent/ECSP045261A/es unknown
- 2004-09-03 HR HR20040800 patent/HRP20040800B1/xx not_active IP Right Cessation
- 2004-10-04 NO NO20044207A patent/NO335099B1/no not_active IP Right Cessation
-
2006
- 2006-01-10 HK HK06100394.6A patent/HK1080375A1/xx not_active IP Right Cessation
-
2007
- 2007-10-31 JP JP2007283678A patent/JP4918456B2/ja not_active Expired - Fee Related
-
2008
- 2008-04-08 US US12/082,104 patent/US7973037B2/en not_active Expired - Lifetime
- 2008-08-19 CY CY20081100883T patent/CY1111130T1/el unknown
-
2011
- 2011-05-25 US US13/115,462 patent/US8318748B2/en not_active Expired - Lifetime
-
2012
- 2012-10-11 US US13/649,670 patent/US8772336B2/en not_active Expired - Lifetime
-
2014
- 2014-05-20 US US14/282,395 patent/US20140256743A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002069901A2 (en) * | 2001-03-02 | 2002-09-12 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100975784B1 (ko) | 카텝신 시스테인 프로테아제 억제제 | |
EP1372655B1 (en) | Cathepsin cysteine protease inhibitors | |
EP1694647B1 (en) | Cathepsin cysteine protease inhibitors | |
KR20070085435A (ko) | 카텝신 시스테인 프로테아제 억제제 | |
JP4553899B2 (ja) | カテプシンシステインプロテアーゼ阻害剤 | |
JP4505329B2 (ja) | カテプシンシステインプロテアーゼ阻害薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130729 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140730 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160629 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170629 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180628 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190624 Year of fee payment: 10 |